CA
PRCT icon

Continuum Advisory’s Procept Biorobotics PRCT Stock Holding History

Continuum Advisory’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12
Closed -$699 – 1263
2025
Q1 		$699 Hold
12
– – ﹤0.01% 1553
2024
Q4 		$966 Hold
12
– – ﹤0.01% 1625
2024
Q3 		$1.03K Buy
+12
New +$853 ﹤0.01% 1615

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Continuum Advisory's PRCT Position: Q2 2025 in Review

Continuum Advisory sold out of Procept Biorobotics (PRCT) in Q2 2025, closing a stake of 12 shares — an estimated $699 sold.

Continuum Advisory first reported a position in PRCT in Q3 2024 and held it in 3 quarters. The position peaked at $1.03K in Q3 2024. 271 funds tracked by Wall St. Rank hold PRCT as of Q2 2025.

  • Continuum Advisory reported no remaining Procept Biorobotics position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 12 Procept Biorobotics shares in Q2 2025, an estimated $699.
  • Continuum Advisory first reported a position in Procept Biorobotics in Q3 2024 and held it in 3 quarters.
  • Continuum Advisory's Procept Biorobotics position peaked at $1.03K in Q3 2024.
  • 271 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.